Fusion Pharmaceuticals price target raised to $16 from $12 at RBC Capital

RBC Capital analyst Gregory Renza raised the firm’s price target on Fusion Pharmaceuticals to $16 from $12 and keeps an Outperform rating on the shares. FPI-2265 stands as the company’s most clinically advanced asset in development for metastatic castration-resistant prostate cancer, with a Phase 2 update coming in April, the analyst tells investors in a research note. The firm maintains its positive stance on risk-reward for the stock, adding that the upcoming disclosure has been largely de-risked by prior IST studies.